Место и роль флударабина в терапии больных неходжкинскими лимфомами (стр. 5 )

38. Zinzani P. L. Idarubicin in low–grade non–Hodgkin’s lymphomas// Haematologica. – 1997. – Vol. 82. – P. 23–24.

39. Zinzani P. L., Magagnoli M., Moretti L. et al. Fludarabine–based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients// Haematologica. – 1999. Vol. 84. – P. 1002–1006.

40. Zinzani P. L., Magagnoli M., Moretti L. et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle–cell lymphoma// J. Clin. Oncol. – 2000. – Vol. 18. – P. 773–779.

41. Densmore J. J., Williams ME. Mantle cell lymphoma// Curr. Treat. Options Oncol. – 2000. – Vol. 1. – P. 281–285.

42. Decaudin D., Bosq J., Tertian G. et al. Phase II trial of fludarabine monophosphate in patients with manle–cell lymphomas// J/ Clin. Oncol. – 1998. – Vol. 16. – P. 579–583.

43. Cohen B. J., Moskowitz C., Straus D. et al. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma// Leuk. Lymphoma. – 2001. – Vol. Vol. 42. – P. 1015–1022.

44. Younes A., Rodriguez M. A., McLaughlin P. et al. Phase I study of fludarabine and paclitaxel for the treatment of low–grade non–Hodgkin’s lymphoma//Leuk. Lymphoma. – 1997. – Vol. 26. – P. 77–82.

45. Glass A. G., Karnell L. H., Menck H. R. The National Cancer Data Base report on non–Hodgkin’s lymphoma// Cancer. – 1997. – Vol. 80. – P. 2311–2315.

46. Jelic S., Milanovic N., Tomasevic Z. et parison of two non–anthracycline–containing regimens for elderly patients with diffuse large–cell non Hodgkin’s lymphoma—possible pitfalls in results reporting and interpretation// Neoplasma. – 1999. – Vol. 46. – P. 394–399.

47. , Абдулкадыров диагностика в гематологической практике. – СПб: « KN», 1997.– 176 с.

48. Crivellari D., Bonetti M., Castiglione–Gertsch M. et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII// J. Clin. Oncol. – 2000. – Vol. 18. – P. 1412–1422.

49. Bordonaro R., Ferrau F., Giuffrida D. et al. Fludarabine as an active and well tolerated salvage therapy in an elderly heavily pretreated Hodgkin’s disease patients: a case report// Tumori. – 1999. – Vol. 85. – P. 288–289.

50. Coiffier B., Neidhardt–Berard E. M., Tilly H. et al. Fludarabine alone compared to CHVP plus interferon in eldery patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d’Etudes des lymphomes de l’Adulte// Ann. Oncol. – 1999. – Vol. 10. – P. 1191–1197.

51. Marotta G., Bigazzi C., Lenoci M. et al. Low–dose fludarabine and cyclophosphamide in elderly patients with B–cell chronic lymphocytic leukemia refractory to conventional therapy// Haematologica. – 2000. – Vol. – 85. – P. 1268–1270.

52. Alas S., Bonavida B., Emmanouilides C. Potentiation of fludarabine cytotoxicity on non–Hodgkin’s lymphoma by pentoxifylline and rituximab// Anticancer Res. – 2000. – Vol. 20, N 5A. – P. 2961–2966.

53. Keating M. J., Flinn I., Jain V. Et al. Therapeutic role of alemtuzumab (Campath–1H) in patients who have failed fludarabine: results of a large international study// Blood. – 2002. – Vol. 99. – P. 3554–3561.

54. , , и др. Результаты 3–х компонентной терапии хронического лимфолейкоза// Актуальные вопросы гематологии и трансфузиологии (материалы Российской научно–практической конференции, посвященной 70–летию Российского научно–исследовательского института гематологии и трансфузиологии, Санкт–Петербург, 18–20 июня 2002 года). – Санкт–Петербург, 2002. – С. 102.

55. Slavin S., Nagler A., Naparstek E. et al. Non–myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease// Blood. – 1998. – Vol. 91. – P. 756–763.

56. Grigg A., Bardy P., Byron K. Fludarabine–based non–myeloablative chemotherapy followed by infusion of HLA–identical stem cells for relapsed leukaemia and lymphoma// Bone Marrow Transplant. – 1999. – Vol. 23. – P. 107–110.

57. Michallet M., Bilger K., Garban F. et al. Allogeneic hematopoietic stem–cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome// J. Clin. Oncol. – 2001. – Vol. 19. – P. 3340–3349.

58. Nagler A., Slavin S., Varadi G. Allogeneic peripheral blood stem cell transplantation using a fludarabine–based low intensity conditioning regimen for malignant lymphoma// Bone Marrow Transplant. – 2000. – Vol. 25. – P. 1021–1028.

rd J. C., Hargis J. B, Kester K. E. et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low–grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis// Am. J. Hematol. – 1995. – Vol. 49. – P. 135–142.

60. Lazzarino M., Orlandi E., Baldanti F. et al. The immunosupression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders// Br. J. Haematol. – 1999. – Vol. 107. – P. 877–882.

61. Shields D. J., Byrd J. C., Abbondanzo S. L. et al. Detection of Epstein–Barr virus in transformations of low–grade B–cell Lymphomas after fludarabine treatment// Mod. Patho. – 1997. – Vol. 10. – P. 1151–1159.

62. Chee Y. L., Culligan D. J., Olson J. A. et al. Sight–threatening varicella zoster virus infection after fludarabine treatment// Br. J. Haematol. – 2000. – Vol. 110. – P. 874–875.

63. Rossi G., Pelizzari A., Motta M., Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy// Br. J. Haematol. – 2001. – Vol. 115. – P. 58–62.

64. Solal–Celigny P., Brice P., Brousse N. et al. Phase II trial of fludarabine monophosphate as first–line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d’Etude des Lymphomes de l’Adulte// J. Clin. Oncol. – 1996. – Vol. 14. – P. 514–519.

65. Garg S., Garg M. S., Basmaji N. Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature// Am. J. Hematol. – 2002. – Vol. 70. – P. 241–245.

66. Weiss R.,; Freiman J., Kweder S. L. et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.// J. Clin. Oncol. – 1998. – Vol. 16. – P. 1885–1889.

67. Misgeld E., Germing U., Aul C., Gattermann N. Secondary myelodysplastic syndrome after fludarabine theraphy of a low–grade non–Hodgkin’s lymphoma// Leuk. Res. – 2001. – Vol. 25. – P. 95–98.

68. Bernasconi P., Orlandi E., Cavigliano P. et al. Translocation (8; 16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low–grade non–Hodgkin’s lymphoma// Haematologica. – 2000. – Vol. 85. – P. 1087–1091.

69. Bocchia M., Bigazzi C., Marconcini S. et al. Favorable impact of low–dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low–grade non–Hodgkin’s lymphomas// Haematologica. – 1999. – Vol. 84. – P. 716–720.

70. Wiedmann E., Boehrer S., Chow K. U. et al. Treatment of aggressive, or progressing indolent peripheral T– and NK–cell neoplasias by combination of fludarabine, cyclofosphamide and doxorubicine// Onkologie. – 2001. – Vol. 24. – P. 162–164.

71. Scarisbrick J. J., Child F. J., Clift A. et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T–cell lymphoma// Br. J. Dermatol. – 2001. – Vol. 144. – P. P. 1010–1015.